naphazoline has been researched along with nafimidone in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (50.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Boddy, AV; Kerr, BM; Levy, RH; Moreland, TA | 1 |
| Alexander, OF; Dow, RJ; Graham, DJ; Hall, DJ; Kurz, L; Rush, WR; Tokes, L | 1 |
| Caccia, S; Conti, I; Fracasso, C; Salmona, M; Testa, R | 1 |
| Caliş, U; Dalkara, S; Ertan, M; Sunal, R | 1 |
| Gunawan, S; Treiman, DM | 2 |
| Durham, DG; Reid, R; Shivji, AS; Taylor, RB | 1 |
| Beedle, EE; Krushinski, JH; Leander, JD; Rathbun, RC; Robertson, DW; Wong, DT | 1 |
| Eadie, J; Graham, DJ; Leadbetter, BM; Metcalf, R | 1 |
| Javitt, NB; Lee, C; Martin, KO | 1 |
| Dalkara, S; Karakurt, A; Kendi, E; Ozalp, M; Ozbey, S; Stables, JP | 1 |
| Alagöz, MA; Calış, U; Dalkara, S; Karakurt, A; Sayoğlu, B | 1 |
| Acar, MF; Dalkara, S; Sari, S | 1 |
| Avci, A; Barut, B; Koçak Aslan, E; Marcinkowska, M; Özel, A; Sabuncuoğlu, S; Sari, S; Siwek, A | 1 |
14 other study(ies) available for naphazoline and nafimidone
| Article | Year |
|---|---|
Pharmacokinetic consequences of product stereoselectivity in the metabolism of nafimidone: estimation of fraction metabolized.
Topics: Animals; Biotransformation; Haplorhini; Naphazoline; Stereoisomerism | 1991 |
The metabolism of nafimidone hydrochloride in the dog, primates and man.
Topics: Adult; Animals; Anticonvulsants; Dogs; Haplorhini; Humans; Imidazoles; Male; Mass Spectrometry; Middle Aged; Naphazoline | 1990 |
Interaction of the anticonvulsants, denzimol and nafimidone, with liver cytochrome P450 in the rat.
Topics: Animals; Anticonvulsants; Biotransformation; Carbamazepine; Cytochrome P-450 Enzyme System; Diazepam; Imidazoles; In Vitro Techniques; Liver; Male; Microsomes, Liver; Naphazoline; Rats; Rats, Inbred Strains; Sleep; Time Factors | 1988 |
The significance of the imidazole ring in anticonvulsant activity of (arylalkyl)imidazoles.
Topics: Animals; Anticonvulsants; Chemical Phenomena; Chemistry; Imidazoles; Male; Mice; Naphazoline | 1988 |
High-performance liquid chromatographic determination of nafimidone and its major metabolite nafimidone alcohol in human plasma and urine.
Topics: Anticonvulsants; Chromatography, High Pressure Liquid; Humans; Imidazoles; Kinetics; Naphazoline | 1987 |
Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy.
Topics: Adult; Anticonvulsants; Chronic Disease; Epilepsy; Female; Half-Life; Humans; Imidazoles; Kinetics; Male; Middle Aged; Naphazoline | 1987 |
Development of a stability-indicating assay for nafimidone [1-(2-naphthoylmethyl)imidazole hydrochloride] by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Hydrogen-Ion Concentration; Imidazoles; Naphazoline; Temperature | 1986 |
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
Topics: Animals; Anticonvulsants; Cerebral Cortex; Chemical Phenomena; Chemistry; Drug Synergism; Female; Flunitrazepam; Hexobarbital; Imidazoles; Mice; Naphazoline; Rats; Rats, Inbred F344; Seizures; Sleep; Structure-Activity Relationship | 1986 |
Simultaneous determination of nafimidone [1-(2-naphthoylmethyl)imidazole], a new anticonvulsant agent, and a major metabolite in plasma by high-performance liquid chromatography.
Topics: Animals; Anticonvulsants; Chromatography, High Pressure Liquid; Dogs; Haplorhini; Humans; Imidazoles; Male; Naphazoline; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 1983 |
Bile acid synthesis: 7 alpha-hydroxylation of intermediates in the sterol 27-hydroxylase metabolic pathway.
Topics: Animals; Bile Acids and Salts; Cell Fractionation; Cholestanetriol 26-Monooxygenase; Cholesterol; Chromatography, High Pressure Liquid; Cricetinae; Cytochrome P-450 Enzyme System; Hydroxycholesterols; Kinetics; Male; Mesocricetus; Microsomes, Liver; Naphazoline; Steroid Hydroxylases; Substrate Specificity | 1996 |
Synthesis of some 1-(2-naphthyl)-2-(imidazole-1-yl)ethanone oxime and oxime ether derivatives and their anticonvulsant and antimicrobial activities.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anticonvulsants; Bacteria; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Electroshock; Ethers; Fungi; Humans; Isomerism; Mice; Microbial Sensitivity Tests; Molecular Conformation; Naphazoline; Oximes; Pentylenetetrazole; Rats; Reflex; Seizures; Structure-Activity Relationship | 2001 |
Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
Topics: Animals; Anticonvulsants; Electroshock; Esters; Imidazoles; Isomerism; Mice; Motor Activity; Naphazoline; Neuropsychological Tests; Oximes; Seizures; Structure-Activity Relationship | 2012 |
Synthesis, in vivo anticonvulsant testing, and molecular modeling studies of new nafimidone derivatives.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Imidazoles; Injections, Intraperitoneal; Male; Mice; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Naphazoline; Rats; Receptors, GABA-A; Seizures; Structure-Activity Relationship | 2019 |
Potential of nafimidone derivatives against co-morbidities of epilepsy: In vitro, in vivo, and in silico investigations.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Epilepsy; Mice; Molecular Docking Simulation; Morbidity; Naphazoline | 2022 |